Disc Medicine Opco Inc (NASDAQ:IRON) Gets Average Buy Recommendation from Brokers

Shares of Disc Medicine Opco Inc (NASDAQ:IRON – Get Rating) have received an average Buy rating from eight analysts covering the stock, according to a Marketbeat.com report. Eight investment analysts rated the stock as a buy. Analysts who covered the stock last year had an average one-year price target of $37.29.

A number of analysts recently released reports on the company. Stifel Nicolaus began reporting on his Disc Medicine Opco in his research notes on Thursday, April 20th. They rated the stock as Buy with a price target of $37.00. SVB Leerink reaffirmed its ‘Outperform’ rating and set a $36.00 price target on Disc Medicine Opco shares in a research note on Tuesday, February 28. Morgan Stanley began coverage of Disc Medicine Opco in a report on Thursday, April 20. They rated the company Overweight with a $37.00 price target. Lifesci Capital reiterated its “outperform” rating for Disc Medicine Opco shares in its research report on Monday, April 24. Finally, Kantor Fitzgerald began reporting on Disc Medicine Opco in a research report on Friday, April 28th. They rated the stock Overweight with a price target of $45.00.

Disk Medicine Opco Inventory Up 2.4 %

IRON shares opened at $33.20 on Monday. Its 50-day moving average is $25.65. The company has a market capitalization of $630.73 million, a price/earnings ratio of -3.32, and a beta of -0.22. Disc Medicine Opco hit a 12-month low of $11.80 and a 12-month high of $35.03.

Institutional Investors Focus on Disc Medicine Opco

A number of institutional investors have recently changed their stakes in the business. Renaissance Technologies LLC raised his stake in Disc Medicine Opco by 17.7% in the first quarter. Renaissance Technologies LLC purchased an additional 2,300 shares last quarter and now owns 15,270 shares worth $324,000. Bank of America Corp. DE raised his stake in Disc Medicine Opco by 134,000.0% in the first quarter. Bank of America Corp DE said he bought an additional 2,680 shares last quarter and now owns 2,682 shares worth $57,000. BlackRock increased its shares in Disc Medicine Opco by 16.9% in the first quarter. BlackRock purchased an additional 3,385 shares last quarter and now owns 23,467 shares worth $497,000. Citigroup Inc. acquired new shares of Disc Medicine Opco worth approximately $101,000 in the fourth quarter. Finally, Barclays PLC increased its holding in Disc Medicine Opco by 2,709.5% in the first quarter. Barclays PLC purchased an additional 5,419 shares during the last quarter and now owns 5,619 shares of the company, valued at $119,000. Institutional investors and hedge funds currently hold 75.42% of the shares.

About Disc Medicine Opco

(get rating)

Disc Medicine, Inc. is a clinical-stage biotechnology company committed to the discovery, development and commercialization of new treatments for patients suffering from serious blood disorders. By targeting fundamental biological pathways of erythrocyte biology, primarily heme biosynthesis and iron homeostasis, we build a portfolio of therapeutic candidates to address various hematological disorders.

Recommended stories

Analyst Recommendations for Disc Medicine Opco (NASDAQ:IRON)

This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments regarding this story to contact@marketbeat.com.

Listen to this before considering Disc Medicine Opco.

MarketBeat tracks Wall Street’s highest-rated, highest-performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are secretly whispering to customers to buy now before the whole market goes viral…and Disc Medicine Opco wasn’t on the list.

Disk Medicine Opco currently has a Buy rating among analysts, but high-scoring analysts think these five stocks are better buys.

Click here for 5 brands

5G Stocks: The Road Ahead Is Profitable Cover

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *